Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of Sepranolone in women with menstrual migraine
2019-001081-15Phase 2Completed
- Sponsor
- Asarina Pharma AB
- Start
- Apr 2019
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sepranolone in Catamenial Migraine (3 arms), sponsored by Asarina Pharma AB. Primary endpoint: Reduction in menstrual migraine days. Started Apr 2019; status: completed.
02
Drugs
sepranolone
03
Conditions
Catamenial Migraine
Beyond the preview
Go deeper on 2019-001081-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001081-15.